Compare Stocks → FW: 234x Gain (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARQTNASDAQ:ELVNNASDAQ:SPRYNASDAQ:TNGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$8.00-7.0%$10.07$1.76▼$15.21$924.24M1.182.71 million shs2.60 million shsELVNEnliven Therapeutics$22.65+7.9%$17.42$9.80▼$26.00$1.06B1.05532,169 shs482,543 shsSPRYARS Pharmaceuticals$9.75+3.1%$9.02$2.55▼$11.27$944.68M0.88536,209 shs364,184 shsTNGXTango Therapeutics$7.61+0.3%$8.58$2.47▼$13.03$812.29M0.84457,721 shs345,845 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-6.98%-5.55%-16.93%+31.80%-46.67%ELVNEnliven Therapeutics+7.91%+31.84%+21.84%+46.98%+14.68%SPRYARS Pharmaceuticals+3.07%+16.77%+3.72%+53.54%+47.73%TNGXTango Therapeutics+0.26%+2.28%-0.91%-40.92%+134.88%Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics1.9307 of 5 stars3.41.00.00.02.72.50.6ELVNEnliven Therapeutics1.7825 of 5 stars3.50.00.00.02.54.20.0SPRYARS Pharmaceuticals3.067 of 5 stars3.51.00.00.03.25.00.6TNGXTango Therapeutics0.6466 of 5 stars3.50.00.00.00.02.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics2.75Moderate Buy$26.56231.94% UpsideELVNEnliven Therapeutics3.00Buy$34.0050.11% UpsideSPRYARS Pharmaceuticals3.00Buy$18.5089.74% UpsideTNGXTango Therapeutics3.00Buy$17.25126.68% UpsideCurrent Analyst RatingsLatest TNGX, SPRY, ELVN, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/9/2024ELVNEnliven TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$34.004/4/2024TNGXTango TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/20/2024TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $17.003/18/2024TNGXTango TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.003/11/2024SPRYARS PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$19.003/5/2024SPRYARS PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/5/2024SPRYARS PharmaceuticalsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$6.00 ➝ $18.002/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.002/23/2024ARQTArcutis BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $16.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$59.61M15.50N/AN/A$0.94 per share8.51ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/ASPRYARS Pharmaceuticals$30K31,489.25N/AN/A$2.40 per share4.06TNGXTango Therapeutics$36.53M22.24N/AN/A$2.48 per share3.07Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Confirmed)ELVNEnliven Therapeutics-$71.58M-$2.19N/AN/AN/AN/A-26.56%-25.18%5/9/2024 (Estimated)SPRYARS Pharmaceuticals-$54.37M-$0.57N/AN/AN/AN/A-22.24%-21.50%5/20/2024 (Estimated)TNGXTango Therapeutics-$101.74M-$1.10N/AN/AN/A-278.55%-41.96%-25.22%5/14/2024 (Estimated)Latest TNGX, SPRY, ELVN, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024N/AARQTArcutis Biotherapeutics-$0.60N/A+$0.60N/AN/AN/A 3/21/2024Q4 2023SPRYARS Pharmaceuticals-$0.14-$0.07+$0.07-$0.07N/AN/A3/18/2024Q4 2023TNGXTango Therapeutics-$0.28-$0.32-$0.04-$0.32$7.86 million$5.43 million3/14/2024Q4 2023ELVNEnliven Therapeutics-$0.56-$0.47+$0.09-$0.47N/AN/A2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics2.287.086.80ELVNEnliven TherapeuticsN/A10.2810.28SPRYARS PharmaceuticalsN/A96.9296.92TNGXTango TherapeuticsN/A7.547.54OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AELVNEnliven Therapeutics95.08%SPRYARS Pharmaceuticals68.16%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics20.70%ELVNEnliven Therapeutics45.80%SPRYARS Pharmaceuticals35.60%TNGXTango Therapeutics6.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics296115.53 million91.61 millionOptionableELVNEnliven Therapeutics4647.01 million25.48 millionOptionableSPRYARS Pharmaceuticals2496.89 million62.40 millionOptionableTNGXTango Therapeutics140106.74 million100.12 millionOptionableELVN, SPRY, TNGX, and ARQT HeadlinesSourceHeadlineInsider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells 60,000 Shares of Stockinsidertrades.com - May 4 at 7:48 AMTango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $456,600.00 in Stockmarketbeat.com - May 3 at 10:24 PMTango Therapeutics (NASDAQ:TNGX) Stock Price Down 7%marketbeat.com - April 25 at 8:44 PMTango Therapeutics (NASDAQ:TNGX) Stock Price Down 3.8%marketbeat.com - April 19 at 1:59 PMTango Therapeutics, Inc. (NASDAQ:TNGX) Expected to Post Q2 2024 Earnings of ($0.34) Per Sharemarketbeat.com - April 18 at 5:59 AMTango Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.33) Per Share (NASDAQ:TNGX)marketbeat.com - April 17 at 4:47 PMFY2024 Earnings Estimate for Tango Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:TNGX)marketbeat.com - April 12 at 6:24 AMVanguard Group Inc. Purchases 197,624 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)marketbeat.com - April 12 at 4:08 AMTango Therapeutics (NASDAQ:TNGX) Shares Down 3.3% marketbeat.com - April 5 at 2:38 PMTango Therapeutics (NASDAQ:TNGX) Stock Price Up 5.2%marketbeat.com - April 4 at 3:08 PMTango Therapeutics (NASDAQ:TNGX) Earns Overweight Rating from Analysts at Cantor Fitzgeraldmarketbeat.com - April 4 at 8:50 AMTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 1 at 4:48 PMBuy Rating Affirmed for Tango Therapeutics on Strong Pipeline and Financial Stabilitymarkets.businessinsider.com - March 21 at 11:58 AMTango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Resultsfinance.yahoo.com - March 20 at 6:57 AMTNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 18 at 4:11 PMRecap: Tango Therapeutics Q4 Earningsbenzinga.com - March 18 at 2:52 PMTango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 18 at 9:10 AMTNGX Aug 2024 20.000 putfinance.yahoo.com - March 11 at 10:26 AMTango Therapeutics to Participate in Upcoming Investor Conferencesbusinesswire.com - March 6 at 7:00 AMTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - March 5 at 4:47 PMCompanies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growthfinance.yahoo.com - March 3 at 9:45 AMTNGX Mar 2024 7.500 callfinance.yahoo.com - February 17 at 8:29 PMTNGX Mar 2024 12.500 callfinance.yahoo.com - February 17 at 3:25 PMPancreatic Cancer Treatments Poised for Major Advances in 2024prnewswire.co.uk - February 7 at 10:27 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Enliven TherapeuticsNASDAQ:ELVNEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.ARS PharmaceuticalsNASDAQ:SPRYARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Tango TherapeuticsNASDAQ:TNGXTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.